Lakefront Biotherapeutics NV (LKFT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lakefront Biotherapeutics NV (LKFT) has a cash flow conversion efficiency ratio of -0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.09 Million) by net assets ($3.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lakefront Biotherapeutics NV stock valuation for the company's overall valuation and market capitalisation.
Lakefront Biotherapeutics NV - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Lakefront Biotherapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Lakefront Biotherapeutics NV (LKFT) share price today for real-time trading data and today's change.
Lakefront Biotherapeutics NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lakefront Biotherapeutics NV ranked by their cash flow conversion efficiency. Review LKFT financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Cisri Gaona Materials Tech
SHE:300034
|
-0.004x |
|
Engineers India Limited
NSE:ENGINERSIN
|
0.018x |
|
Shandong Pharmaceutical Glass Co Ltd
SHG:600529
|
0.005x |
|
China National Gold Group Gold Jewellery Co Ltd
SHG:600916
|
0.003x |
|
Genesis Energy LP
NYSE:GEL
|
0.153x |
|
BTG Hotels Group Co Ltd
SHG:600258
|
0.084x |
|
Zhejiang Jinke Peroxides Co Ltd
SHE:300459
|
0.029x |
|
Shenzhen Topband Co Ltd
SHE:002139
|
0.029x |
Annual Cash Flow Conversion Efficiency for Lakefront Biotherapeutics NV (2022–2025)
The table below shows the annual cash flow conversion efficiency of Lakefront Biotherapeutics NV from 2022 to 2025. Also see total assets of Lakefront Biotherapeutics NV for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.24 Billion | $-257.46 Million | -0.080x | +27.98% |
| 2024-12-31 | $2.90 Billion | $-320.03 Million | -0.110x | +23.93% |
| 2023-12-31 | $2.80 Billion | $-405.97 Million | -0.145x | +26.71% |
| 2022-12-31 | $2.53 Billion | $-500.54 Million | -0.198x | -- |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more